Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$90.78+9.10%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TARS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks TARS against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue expanding sales of XDEMVY for Demodex blepharitis with increased market adoption and direct-to-consumer campaigns.
Stated as a priority in 2 of last 2 quarters. XDEMVY net product sales increased from $145.4 million in 2026-Q1 to $173.9 million in 2026-Q2, a year-over-year growth exceeding 69%. Management emphasizes strong demand and commercial execution, indicating the growth trajectory is delivering.
“XDEMVY generated second quarter 2026 net product sales of $173.9 million, a year-over-year increase of more than 69%.”
“Generated first quarter XDEMVY net product sales of more than $145 million, an increase of more than 85% year-over-year.”
Progress clinical-stage programs and expand pipeline through acquisitions like iRenix Medical and Alkeus Pharmaceuticals.
Stated in 2 recent disclosures including 2026-Q2 press release and July 2026 acquisition announcement. The company completed acquisition of iRenix Medical and agreed to acquire Alkeus Pharmaceuticals, advancing late-stage clinical assets. This reflects active pipeline expansion and clinical progress, delivering on stated growth strategy.
“Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3 clinical program for Stargardt disease.”
Increase patient engagement and awareness of Demodex blepharitis through DTC campaigns and promotional efforts.
Stated in 2 of last 2 quarters. DTC campaigns increased website engagement by over 30% in 2026-Q2 and approximately 40% quarter-over-quarter in 2026-Q1, supporting prescription growth. Management continues to emphasize this as a key driver, indicating delivery on patient awareness expansion.
“Direct-to-consumer initiatives continued to contribute to prescription growth and awareness, with website engagement up more than 30%.”
Address changes in commercial leadership including appointment of interim Chief Commercial Officer.
Stated in 2 recent disclosures including 2026-Q2 press release and July 2026 officer change. Management appointed an interim Chief Commercial Officer following the departure of the prior CCO, indicating active management of leadership transitions. This priority is ongoing with mixed delivery as transitions occur.
“Appointed Neera Clase, Interim Chief Commercial Officer as the Company enters its next phase of growth.”
Raise 2026 annual net product sales guidance for XDEMVY to $685-705 million reflecting strong sales momentum.
Stated in 2 of last 2 quarters. Management raised full-year 2026 XDEMVY net product sales guidance from $670-700 million in 2026-Q1 to $685-705 million in 2026-Q2, reflecting confidence in sales momentum. This upward revision matches the strong quarterly sales growth, indicating delivery on guidance improvement.
“Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million.”
Over the trailing year it converted 1.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“DTC campaign drove tremendous engagement and increased high-value actions on the website by approximately 40% quarter-over-quarter.”
“Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales.”